Clinical trials: NHL
NHL, Adult, AML, Adult Recurrent
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
This Trial is an open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with AML and NHL who previously received standard treatment or are…
- Trial name
- NCT05758610
- Testing
- ETH-155008
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shengke Pharmaceuticals (Jiangsu) Limited, China
B-cell NHL, CLL
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
This is a single arm, open-label, multi-center, phase I/II study to determine the engraftment, safety and clinical activity of allogeneic CARCIK-CD19 cells in adult and pediatric patients with relapsed/refractory mature B-cell…
- Trial name
- NCT05869279
- Testing
- CARCIK-CD19
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
B-NHL
An Evaluation of LY007 Cell Injection for r/r B-NHL
An evaluation of LY007 cell injection for recurrent/refractory CD20 was positive Tolerability, safety, and efficacy of B-cell non-Hodgkin lymphoma in open, single-arm Phsea I Clinical research
- Trial name
- r/r B-NHL (NCT06364852)
- Testing
- LY007
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
B-NHL
An Evaluation of LY007 Cell Injection for r/r B-NHL
An evaluation of LY007 cell injection for recurrent/refractory CD20 was positive Tolerability, safety, and efficacy of B-cell non-Hodgkin lymphoma in open, single-arm Phsea I Clinical research
- Trial name
- r/r B-NHL (NCT06279611)
- Testing
- LY007
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Longyao Biotechnology Inc., Ltd.
NHL, Adult
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-1252 single agent and in combination with other therapeutic agent in patients with NHL.
- Trial name
- NCT05186012
- Testing
- APG-1252, Chidamide
- Where
- 4 sites in China
- Volunteers
- 51 people
- Sponsor
- Ascentage Pharma Group Inc.
NHL, Leukemia
First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
This Trial is a FIH, open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with R/R B-cell NHL, CLL/SLL and AML who previously received standard…
- Trial name
- NCT04840784
- Testing
- ETH-155008
- Where
- 5 sites in Australia
- Volunteers
- 9 people
- Sponsor
- Shengke Pharmaceuticals Pty Ltd
Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL)
Safety and Efficacy Evaluation of CD19-UCART
The purpose of this study is to evaluate the safety and efficacy of ascending doses of CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.
- Trial name
- NCT03229876
- Testing
- CD19-UCART
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Bioray Laboratories
Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma
This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114…
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT05144347
- Testing
- XL114
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Exelixis
Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Phase IIa study to estimate the efficacy of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as CART-19 or CTL019…
- Trial name
- NCT02030834
- Testing
- CART-19
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Pennsylvania
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Non-Hodgkin's Lymphoma (NHL)
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
According to amendment 3 this study addresses the question if intensification of administration of rituximab in standard treatment for patients with newly diagnosed aggressive B-Non Hodgkin Lymphoma (B-NHL) and high risk (aaIPI 2…
- Trial name
- NCT00129090
- Testing
- R-CHOEP 14 with 12x Rituximab
- Where
- Germany
- Volunteers
- 450 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
B Cell NHL, CLL
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.
This is a Phase 1/2 study of GB261 in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage(Phase 1), an expansion stage(Phase 2a) and Phase 2b stage where participants…
- Trial name
- NCT04923048
- Testing
- GB261
- Where
- 6 sites in Australia
- Volunteers
- 460 people
- Sponsor
- Genor Biopharma Co., Ltd.
NHL, Relapsed, Adult, B-cell Lymphoma
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).
- Conditions
- NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma
- Trial name
- ANCHOR2 (NCT05487651)
- Testing
- KUR-502
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Athenex, Inc.
Multiple Myeloma, Acute Myeloid Leukemia
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome
- Trial name
- NCT03465540
- Testing
- AMG 397, Dexamethasone, Azacitidine
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 24 people
- Sponsor
- Amgen
CLL/SLL, NHL
A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL
This is a Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN102 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin's Lymphoma…
- Trial name
- NCT05365100
- Testing
- BN102
- Where
- 6 sites in China
- Sponsor
- BioNova Pharmaceuticals (Shanghai) LTD.
Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL)
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with hematopoietic and lymphoid malignancies.
- Conditions
- Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL), Multiple Myeloma (MM), T-Cell Leukemia/Lymphoma, Adult
- Trial name
- NCT05513612
- Testing
- Autologous CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Sponsor
- Shanghai Pudong Hospital
CLL/SLL, NHL
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL
- Conditions
- CLL/SLL, NHL, MCL, MZL
- Trial name
- NCT05176691
- Testing
- HMPL-760
- Where
- 36 sites in United States, Australia and 5 more
- Sponsor
- Hutchmed
Relapsed or Refractory B-cell Malignancy(NHL/ALL)
A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)
The purpose of this study is to evaluate the safety and efficacy of CD19-UCART in patients with r/r B-cell hematological malignancies.
- Trial name
- NCT04933825
- Testing
- ET-02
- Where
- China
- Volunteers
- 18 people
- Sponsor
- EdiGene (GuangZhou) Inc.
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited, r/r B-NHL
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
This is a single dose escalation study to evaluate the safety, efficacy and pharmacokinetics of ThisCART19A (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell Lymphoma.
- Trial name
- NCT05535673
- Testing
- ThisCART19A
- Volunteers
- 15 people
- Sponsor
- Zhengzhou University
T-ALL, T-NHL (Lymphoblastic)
506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)
The purpose of this study is to determine whether Nelarabine is effective in the treatment of patients with T-ALL/NHL in order to achieve a complete remission followed by an early stem cell transplantation.
- Trial name
- NCT00684619
- Testing
- Nelarabine
- Where
- 11 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Goethe University